

November 6, 2021, Orlando, USA.

TiDES-ACS Results Confirm Superiority of TiTAN OPTiMAX® versus SYNERGY® at 3 years

New research findings released at TCT 2021 (Transcatheter Cardiovascular Therapeutics, the world's premier meeting for interventional cardiovascular medicine) show that the TiTAN OPTiMAX bioactive stent coated with titanium-nitride-oxide (Hexacath, Paris, France) has maintained its superiority over the best-in-class drug-eluting-stent SYNERGY (Boston Scientific) in Acute Coronary Syndrome patients (ACS, myocardial infarction with ST elevation and myocardial infarction without ST elevation) through 3 years of clinical follow up.

The findings come from TiDES-ACS, a randomised international prospective trial involving nearly 1500 patients suffering from myocardial infarction. The 3-year results were presented by co-principal investigator Pr Pasi Karjalainen, Heart and Lung Center, Helsinki University Hospital, Helsinki Finland. The data showed non-inferiority at 12 and 36 months follow up for the primary composite outcome of Major Cardiac Events (MACE) : 10.1% with TiTAN OPTiMAX and 12.4% with SYNERGY and statistically significant differences favouring the TiTAN OPTiMAX demonstrating sustained superiority versus SYNERGY for the co-primary endpoint of safety between 12 and up to 36 months follow up. The 3-year results from TiDES-ACS randomized trial confirm the long-term clinical outcomes should be an essential consideration when making decisions related to stent selection when treating patients with Acute Coronary Syndrome one of the most complex situation in angioplasty due to inflammation, pro-thrombotic conditions and acute ischemic risks putting the patient's life in immediate danger.

Titanium-nitride-oxide coated bioactive stent (TiTAN OPTiMAX, Hexacath) is a leading innovation to treat patients suffering from heart attack/myocardial infarction. In addition, this unique technology has demonstrated faster healing as early as 14 days post stent implantation in OCT published studies thus helping doctors to ease the patient management post PCI procedure.

At Hexacath, we are proud of being able to contribute to advancing life-saving medical technology providing interventional cardiologists new tools to help them saving lives of patients affected with cardio vascular diseases which are the leading cause of death globally accounting for 32% of all global deaths worldwide (WHO 2021).

Congratulations to Pr Karjalainen, all TiDES-ACS participating centers and to all the distinguished experts from the panel for this exciting and brilliant session!

#TCT 2021 #CRF Foundation #Featured Clinical Research Session III #Stephen G. Ellis #Martin B. Leon #Daniel Burkhoff #Nadira Hamid #Pasi Karjalainen #Kenneth Chin #Runlin Gao #Stefan K. James #Adnan Kastrati #Yoshinobu Onuma

